Cremophor EL-based nanoemulsion enhances transcellular permeation of emodin through glucuronidation reduction in UGT1A1-overexpressing MDCKII cells

2016 ◽  
Vol 501 (1-2) ◽  
pp. 190-198 ◽  
Author(s):  
Tianpeng Zhang ◽  
Dong Dong ◽  
Danyi Lu ◽  
Shuai Wang ◽  
Baojian Wu
Keyword(s):  
2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Shih-Tien Hsu ◽  
Chun-Hsu Yao ◽  
Yuan-Man Hsu ◽  
Jia-Horng Lin ◽  
Yung-Hsiang Chen ◽  
...  

Abstract Recent studies describe taxol as a candidate treatment for promoting central nerve regeneration. However, taxol has serious side effects including peripheral neurotoxicity, and little information is known about the effect of taxol on peripheral nerve regeneration. We investigated the effects of taxol on regeneration in a rat sciatic nerve transection model. Rats were divided into four groups (n = 10): normal saline (i.p.) as the control, Cremophor EL vehicle, and 2 or 6 mg/kg of taxol in the Cremophor EL solution (four times in day-2, 4, 6, and 8), respectively. We evaluated neuronal electrophysiology, animal behaviour, neuronal connectivity, macrophage infiltration, location and expression levels of calcitonin gene-related peptide (CGRP), and expression levels of both nerve growth factors and immunoregulatory factors. In the high-dose taxol group (6 mg/kg), neuronal electrophysiological function was significantly impaired. Licking latencies were significantly changed while motor coordination was unaffected. Neuronal connectivity, macrophage density, and expression levels of CGRP was dramatically reduced. Expression levels of nerve growth factors and immunoregulatory factors was also reduced, while it was increased in the low-dose taxol group (2 mg/kg). These results indicate that taxol can modulate local inflammatory conditions, impair nerve regeneration, and impede recovery of a severe peripheral nerve injury.


1994 ◽  
Vol 5 ◽  
pp. 32
Author(s):  
Marie-Louise Fällskog ◽  
Lena Frii ◽  
Jonas Bergh

1990 ◽  
Vol 62 (4) ◽  
pp. 591-594 ◽  
Author(s):  
GJ Schuurhuis ◽  
HJ Broxterman ◽  
HM Pinedo ◽  
ThHM van Heijningen ◽  
CK van Kalken ◽  
...  

Author(s):  
E. Giffon ◽  
P. Jean ◽  
D. Vervloet
Keyword(s):  

2011 ◽  
Vol 2011 ◽  
pp. 1-10 ◽  
Author(s):  
Ying Wang ◽  
Ke-Chun Wu ◽  
Bing-Xiang Zhao ◽  
Xin Zhao ◽  
Xin Wang ◽  
...  

The purpose of this study was to prepare a novel paclitaxel (PTX) microemulsion containing a reduced amount of Cremophor EL (CrEL) which had similar pharmacokinetics and antitumor efficacy as the commercially available PTX injection, but a significantly reduced allergic effect due to the CrEL. The pharmacokinetics, biodistribution,in vivoantitumor activity and safety of PTX microemulsion was evaluated. The results of pharmacokinetic and distribution properties of PTX in the microemulsion were similar to those of the PTX injection. The antitumor efficacy of the PTX microemulsion in OVCRA-3 and A 549 tumor-bearing animals was similar to that of PTX injection. The PTX microemulsion did not cause haemolysis, erythrocyte agglutination or simulative reaction. The incidence and degree of allergic reactions exhibited by the PTX microemulsion group, with or without premedication, were significantly lower than those in the PTX injection group (P<.01). In conclusion, the PTX microemulsion had similar pharmacokinetics and anti-tumor efficacy to the PTX injection, but a significantly reduced allergic effect due to CrEL, indicating that the PTX microemulsion overcomes the disadvantages of the conventional PTX injection and is one way of avoiding the limitations of current injection product while providing suitable therapeutic efficacy.


2010 ◽  
Vol 39 (2) ◽  
pp. 247-255 ◽  
Author(s):  
Martin N. Fransson ◽  
Henrik Gréen ◽  
Jan-Eric Litton ◽  
Lena E. Friberg

2015 ◽  
Vol 30 (3) ◽  
pp. 221-226 ◽  
Author(s):  
Atsuko Tomaru ◽  
Mariko Takeda-Morishita ◽  
Kazuya Maeda ◽  
Hirokazu Banba ◽  
Kozo Takayama ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document